Our mission is bold: to collaboratively optimize and accelerate the development of new cancer therapies for the benefit of patients of all ages. 

We aim to achieve this by integrating patient data and materials -including patient-derived organoid models- and artificial intelligence at early stages of preclinical therapy development, across four pipelines focused on developing oncology-targeted therapeutics: 

- Small molecules, 
- Biologics, 
- Cell and gene therapies, and 
- Therapeutic vaccines. 

Our world-class toolbox of state-of-the-art technologies, is available through Demonstrator Projects to anyone globally that has a target of interest and/or a validated hit, and who wishes to advance their asset to a valuable clinical candidate. Ultimately, our integrated approach and top notch infrastructure should result in more effective, personalized cancer therapies. This will bring us closer to our overarching goal: to outsmart cancer and impact lives. 

Oncode Accelerator is a public-private partnership that is funded by the Dutch National Growth Fund (NGF). It is a collaboration between six coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation.

Oncode Accelerator

Org chart

Teams

Offices